TRT side effects and peptide support: what the evidence says

What did @thenovuscenter_ actually say?

The creator claims that testicular shrinkage on TRT happens because "you are not taking something to stimulate your testicles," and that two peptides, gonadorelin and kisspeptin, can keep the testes "motivated" to keep producing testosterone. The pitch is that using either peptide means "you don't need as much injectable testosterone." That last part is the most commercially loaded claim in the video, and it deserves real scrutiny.

The video is short and moves fast. It names the mechanism (LH suppression), names the drugs, and implies a clean fix. That makes it appealing to someone three weeks into TRT who just noticed something feels different in the shower. Whether the science actually supports that clean a story is another matter.

Does the science back this up?

Partially, yes. The core biology is real. Exogenous testosterone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, which drops LH from the pituitary, which leaves Leydig cells unstimulated, which causes testicular atrophy and reduces endogenous testosterone production. That chain is well-established (Boregowda et al., 2023, Journal of Clinical Endocrinology and Metabolism).

Gonadorelin is a synthetic GnRH analog. It works upstream of LH, not identically to it. Kisspeptin also works upstream, stimulating GnRH release. Neither one "looks identical to luteinizing hormone" as the creator says. That is a real biological error. The clinical evidence for gonadorelin preserving testicular volume during TRT is mostly from small studies and compounding-pharmacy use cases, not large randomized trials. Kisspeptin's TRT-adjunct data is even thinner, largely confined to research settings (Jayasena et al., 2014, Journal of Clinical Investigation).

What did they get wrong (or right)?

They got the problem right. Testicular atrophy on TRT is common and driven by LH suppression. Credit where it's due.

They got the mechanism wrong. The creator says gonadorelin and kisspeptin "look identical to luteinizing hormone." They do not. Gonadorelin is a GnRH analog. It triggers the pituitary to release LH; it is not LH itself. Kisspeptin triggers GnRH release, one step further upstream. This is not a small distinction. If someone's pituitary is compromised, GnRH analogs will not produce LH no matter how much you use. The mechanism matters for patient selection.

The claim that using these peptides means "you don't need as much injectable testosterone" is not supported by robust clinical evidence. It is biologically plausible but has not been demonstrated in well-powered trials to reduce TRT dosing requirements in a clinically meaningful, reproducible way. Presenting it as a predictable outcome is overselling the data.

• Gonadorelin is a GnRH agonist, not an LH analog.
• Kisspeptin stimulates GnRH, not LH directly.
• The "need less testosterone" claim lacks strong clinical trial support.

What should you actually know?

If preserving testicular size and function matters to you during TRT, there are legitimate options. Human chorionic gonadotropin (hCG) has the strongest evidence base for this purpose because it directly mimics LH at the Leydig cell receptor (Coviello et al., 2005, Journal of Clinical Endocrinology and Metabolism). Gonadorelin is increasingly used as a compounded hCG alternative since the FDA removed hCG from the outsourcing facility list for certain preparations, but the data supporting gonadorelin specifically for testicular preservation is much thinner.

Kisspeptin is largely still a research compound for this application. Using it in a clinical TRT context is not standard of care anywhere with solid evidence behind it. That does not mean it is dangerous, but patients deserve to know the evidence hierarchy.

Anyone on TRT who is concerned about testicular atrophy, fertility preservation, or endogenous testosterone suppression should have this conversation with a licensed prescriber who can order appropriate labs, including LH, FSH, and a semen analysis if fertility is relevant. A TikTok video is not a treatment plan.

Bottom line

The video identifies a real problem and real drug categories, but misrepresents how those drugs work at a mechanistic level. Calling gonadorelin and kisspeptin LH look-alikes is simply incorrect, and the implication that they will reduce your TRT dose requirements is not backed by the clinical literature in any reliable way. The intent seems educational, but the inaccuracies are significant enough to matter in a clinical context.